111 related articles for article (PubMed ID: 9576370)
1. Pharmacokinetics of clodronate in peritoneal dialysis patients.
Saha HH; Ala-Houhala IO; Liukko-Sipi SH; Ylitalo P; Pasternack AI
Perit Dial Int; 1998; 18(2):204-9. PubMed ID: 9576370
[TBL] [Abstract][Full Text] [Related]
2. Skeletal deposition of clodronate is related to parathyroid function and bone turnover in dialysis patients.
Saha H; Ala-Houhala I; Ylitalo P; Kleimola T; Pasternack A
Clin Nephrol; 2002 Jul; 58(1):47-53. PubMed ID: 12141406
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of clodronate in haemodialysis patients.
Ala-Houhala I; Saha H; Liukko-Sipi S; Ylitalo P; Pasternack A
Nephrol Dial Transplant; 1999 Mar; 14(3):699-705. PubMed ID: 10193822
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of clodronate in renal failure.
Saha H; Castren-Kortekangas P; Ojanen S; Juhakoski A; Tuominen J; Tokola O; Pasternack A
J Bone Miner Res; 1994 Dec; 9(12):1953-8. PubMed ID: 7872061
[TBL] [Abstract][Full Text] [Related]
5. Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.
Keller E; Reetze P; Schollmeyer P
Clin Pharmacokinet; 1990 Feb; 18(2):104-17. PubMed ID: 2180611
[TBL] [Abstract][Full Text] [Related]
6. Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics.
Gerig JS; Bolton ND; Swabb EA; Scheld WM; Bolton WK
Kidney Int; 1984 Sep; 26(3):308-18. PubMed ID: 6542606
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients.
Manley HJ; Bailie GR; Asher RD; Eisele G; Frye RF
Perit Dial Int; 1999; 19(1):65-70. PubMed ID: 10201343
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis.
Pauli-Magnus C; Hofmann U; Mikus G; Kuhlmann U; Mettang T
Nephrol Dial Transplant; 1999 Apr; 14(4):903-9. PubMed ID: 10328468
[TBL] [Abstract][Full Text] [Related]
9. Independent effects of renal and peritoneal clearances on the mortality of peritoneal dialysis patients.
Szeto CC; Wong TY; Chow KM; Leung CB; Law MC; Li PK
Perit Dial Int; 2004; 24(1):58-64. PubMed ID: 15104337
[TBL] [Abstract][Full Text] [Related]
10. Single-dose pefloxacin pharmacokinetics and metabolism in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Nikolaidis P; Walker SE; Dombros N; Tourkantonis A; Paton TW; Oreopoulos DG
Perit Dial Int; 1991; 11(1):59-63. PubMed ID: 2049424
[TBL] [Abstract][Full Text] [Related]
11. Elimination of iomeprol in patients undergoing continuous ambulatory peritoneal dialysis.
Iwamoto M; Hiroshige K; Suda T; Ohta T; Ohtani A; Nakashima Y
Perit Dial Int; 1999; 19(4):380-5. PubMed ID: 10507822
[TBL] [Abstract][Full Text] [Related]
12. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group.
Weinreich T; Ritz E; Passlick-Deetjen J
Perit Dial Int; 1996; 16(3):260-8. PubMed ID: 8761540
[TBL] [Abstract][Full Text] [Related]
13. Appropriate drug dosing in patients receiving peritoneal dialysis.
Hirata S; Kadowaki D
Contrib Nephrol; 2012; 177():30-37. PubMed ID: 22613912
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of teicoplanin in patients undergoing continuous ambulatory peritoneal dialysis.
Stamatiadis D; Papaioannou MG; Giamarellos-Bourboulis EJ; Marinaki S; Giamarellou H; Stathakis CP
Perit Dial Int; 2003; 23(2):127-31. PubMed ID: 12713078
[TBL] [Abstract][Full Text] [Related]
15. Azithromycin: an assessment of its pharmacokinetics and therapeutic potential in CAPD.
Kent JR; Almond MK; Dhillon S
Perit Dial Int; 2001; 21(4):372-7. PubMed ID: 11587400
[TBL] [Abstract][Full Text] [Related]
16. Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose.
Heimbürger O; Stenvinkel P; Berglund L; Tranoeus A; Lindholm B
Nephron; 1996; 72(2):135-44. PubMed ID: 8684516
[TBL] [Abstract][Full Text] [Related]
17. Peritoneal clearance of leptin in continuous ambulatory peritoneal dialysis.
Arkouche W; Juillard L; Delawari E; Lasne Y; Combarnous F; Sibaï-Galland R; Traeger J; Laville M; Fouque D
Am J Kidney Dis; 1999 Nov; 34(5):839-44. PubMed ID: 10561139
[TBL] [Abstract][Full Text] [Related]
18. Endothelin-1 in continuous ambulatory peritoneal dialysis and hemodialysis patients: a preliminary study.
Lightfoot BO; Caruana RJ
Perit Dial Int; 1993; 13(1):55-8. PubMed ID: 8443279
[TBL] [Abstract][Full Text] [Related]
19. The effect of continuous ambulatory peritoneal dialysis on change in serum leptin.
Kim DJ; Oh DJ; Kim B; Lim YH; Kang WH; Lee BH; Lee SK; Huh W; Kim SE; Lee MK; Kang SA; Oh HY
Perit Dial Int; 1999; 19 Suppl 2():S172-5. PubMed ID: 10406513
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of flecainide in a patient undergoing continuous ambulatory peritoneal dialysis.
Bailie GR; Waldek S
J Clin Pharm Ther; 1988 Apr; 13(2):121-4. PubMed ID: 3134365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
